Published in Cancer Weekly, February 5th, 2008
Oncology News International profiled InNexus' Dynamic Cross Linking technology in their recent issue concerning how InNexus Biotechnology's technology could be used to improve the target-binding affinity of existing monoclonal antibodies (MoAbs) as well as those in development.
The full text of the Oncology News...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.